New  ||| S:0 E:4 ||| JJ
non-pharmacological  ||| S:4 E:24 ||| JJ
treatment  ||| S:24 E:34 ||| NN
methods  ||| S:34 E:42 ||| NNS
in  ||| S:42 E:45 ||| IN
heart  ||| S:45 E:51 ||| NN
failure  ||| S:51 E:59 ||| NN
The  ||| S:59 E:63 ||| DT
incidence  ||| S:63 E:73 ||| NN
of  ||| S:73 E:76 ||| IN
chronic  ||| S:76 E:84 ||| JJ
heart  ||| S:84 E:90 ||| NN
failure  ||| S:90 E:98 ||| NN
( ||| S:98 E:99 ||| -LRB-
CHF ||| S:99 E:102 ||| NNP
)  ||| S:102 E:104 ||| -RRB-
increases  ||| S:104 E:114 ||| NNS
with  ||| S:114 E:119 ||| IN
the  ||| S:119 E:123 ||| DT
aging  ||| S:123 E:129 ||| VBG
of  ||| S:129 E:132 ||| IN
the  ||| S:132 E:136 ||| DT
population  ||| S:136 E:147 ||| NN
and  ||| S:147 E:151 ||| CC
with  ||| S:151 E:156 ||| IN
the  ||| S:156 E:160 ||| DT
improvement  ||| S:160 E:172 ||| NN
in  ||| S:172 E:175 ||| IN
survival  ||| S:175 E:184 ||| NN
of  ||| S:184 E:187 ||| IN
patients  ||| S:187 E:196 ||| NNS
with  ||| S:196 E:201 ||| IN
hypertension ||| S:201 E:213 ||| NN
,  ||| S:213 E:215 ||| ,
coronary  ||| S:215 E:224 ||| JJ
heart  ||| S:224 E:230 ||| NN
disease  ||| S:230 E:238 ||| NN
and  ||| S:238 E:242 ||| CC
diabetes ||| S:242 E:250 ||| NN
,  ||| S:250 E:252 ||| ,
diseases  ||| S:252 E:261 ||| NNS
which  ||| S:261 E:267 ||| WDT
constitute  ||| S:267 E:278 ||| VBP
the  ||| S:278 E:282 ||| DT
most  ||| S:282 E:287 ||| RBS
common  ||| S:287 E:294 ||| JJ
causes  ||| S:294 E:301 ||| NNS
for  ||| S:301 E:305 ||| IN
the  ||| S:305 E:309 ||| DT
development  ||| S:309 E:321 ||| NN
of  ||| S:321 E:324 ||| IN
CHF ||| S:324 E:327 ||| NNP
.  ||| S:327 E:329 ||| .
Despite  ||| S:329 E:337 ||| IN
the  ||| S:337 E:341 ||| DT
significant  ||| S:341 E:353 ||| JJ
improvement  ||| S:353 E:365 ||| NN
in  ||| S:365 E:368 ||| IN
the  ||| S:368 E:372 ||| DT
treatment  ||| S:372 E:382 ||| NN
of  ||| S:382 E:385 ||| IN
patients  ||| S:385 E:394 ||| NNS
with  ||| S:394 E:399 ||| IN
CHF ||| S:399 E:402 ||| NNP
,  ||| S:402 E:404 ||| ,
mortality  ||| S:404 E:414 ||| NN
in  ||| S:414 E:417 ||| IN
recent  ||| S:417 E:424 ||| JJ
years  ||| S:424 E:430 ||| NNS
has  ||| S:430 E:434 ||| VBZ
improved  ||| S:434 E:443 ||| VBN
slightly ||| S:443 E:451 ||| RB
.  ||| S:451 E:453 ||| .
The  ||| S:453 E:457 ||| DT
primary  ||| S:457 E:465 ||| JJ
treatment  ||| S:465 E:475 ||| NN
method  ||| S:475 E:482 ||| NN
for  ||| S:482 E:486 ||| IN
chronic  ||| S:486 E:494 ||| JJ
heart  ||| S:494 E:500 ||| NN
failure  ||| S:500 E:508 ||| NN
is  ||| S:508 E:511 ||| VBZ
pharmacotherapy ||| S:511 E:526 ||| VBN
,  ||| S:526 E:528 ||| ,
but  ||| S:528 E:532 ||| CC
it  ||| S:532 E:535 ||| PRP
has  ||| S:535 E:539 ||| VBZ
limitations ||| S:539 E:550 ||| NNS
.  ||| S:550 E:552 ||| .
The  ||| S:552 E:556 ||| DT
existing  ||| S:556 E:565 ||| JJ
data  ||| S:565 E:570 ||| NN
encourages  ||| S:570 E:581 ||| VBZ
to  ||| S:581 E:584 ||| TO
look  ||| S:584 E:589 ||| VB
for  ||| S:589 E:593 ||| IN
new  ||| S:593 E:597 ||| JJ
treatment  ||| S:597 E:607 ||| NN
methods  ||| S:607 E:615 ||| NNS
for  ||| S:615 E:619 ||| IN
CHF ||| S:619 E:622 ||| NNP
,  ||| S:622 E:624 ||| ,
replacing  ||| S:624 E:634 ||| VBG
or  ||| S:634 E:637 ||| CC
enhancing  ||| S:637 E:647 ||| VBG
traditional  ||| S:647 E:659 ||| JJ
ones  ||| S:659 E:664 ||| NNS
while  ||| S:664 E:670 ||| IN
constituting  ||| S:670 E:683 ||| VBG
a  ||| S:683 E:685 ||| DT
low  ||| S:685 E:689 ||| JJ
nuisance  ||| S:689 E:698 ||| NN
for  ||| S:698 E:702 ||| IN
patients ||| S:702 E:710 ||| NNS
.  ||| S:710 E:712 ||| .
New  ||| S:712 E:716 ||| JJ
non-pharmacological  ||| S:716 E:736 ||| JJ
methods ||| S:736 E:743 ||| NNS
,  ||| S:743 E:745 ||| ,
including  ||| S:745 E:755 ||| VBG
therapies  ||| S:755 E:765 ||| NNS
based  ||| S:765 E:771 ||| VBN
on  ||| S:771 E:774 ||| IN
the  ||| S:774 E:778 ||| DT
use  ||| S:778 E:782 ||| NN
of  ||| S:782 E:785 ||| IN
stem  ||| S:785 E:790 ||| JJ
cells ||| S:790 E:795 ||| NNS
,  ||| S:795 E:797 ||| ,
molecular  ||| S:797 E:807 ||| JJ
therapy ||| S:807 E:814 ||| NN
,  ||| S:814 E:816 ||| ,
modern  ||| S:816 E:823 ||| JJ
devices  ||| S:823 E:831 ||| NNS
supporting  ||| S:831 E:842 ||| VBG
the  ||| S:842 E:846 ||| DT
heart  ||| S:846 E:852 ||| NN
such  ||| S:852 E:857 ||| JJ
as  ||| S:857 E:860 ||| IN
cardiac  ||| S:860 E:868 ||| JJ
contractility  ||| S:868 E:882 ||| JJ
modulation ||| S:882 E:892 ||| NN
,  ||| S:892 E:894 ||| ,
spinal  ||| S:894 E:901 ||| JJ
cord  ||| S:901 E:906 ||| NN
stimulation ||| S:906 E:917 ||| NN
,  ||| S:917 E:919 ||| ,
carotid  ||| S:919 E:927 ||| FW
sinus  ||| S:927 E:933 ||| FW
nerve  ||| S:933 E:939 ||| FW
stimulation ||| S:939 E:950 ||| FW
,  ||| S:950 E:952 ||| ,
cervical  ||| S:952 E:961 ||| NN
and  ||| S:961 E:965 ||| CC
intracardiac  ||| S:965 E:978 ||| FW
atrioventricular  ||| S:978 E:995 ||| FW
nodal  ||| S:995 E:1001 ||| FW
vagal  ||| S:1001 E:1007 ||| FW
stimulation ||| S:1007 E:1018 ||| FW
,  ||| S:1018 E:1020 ||| ,
implantable  ||| S:1020 E:1032 ||| JJ
monitoring  ||| S:1032 E:1043 ||| NN
devices  ||| S:1043 E:1051 ||| NNS
and  ||| S:1051 E:1055 ||| CC
wearable  ||| S:1055 E:1064 ||| JJ
cardioverter-defibrillator  ||| S:1064 E:1091 ||| JJ
or  ||| S:1091 E:1094 ||| CC
the  ||| S:1094 E:1098 ||| DT
treatment  ||| S:1098 E:1108 ||| NN
of  ||| S:1108 E:1111 ||| IN
comorbid  ||| S:1111 E:1120 ||| JJ
diseases  ||| S:1120 E:1129 ||| NNS
such  ||| S:1129 E:1134 ||| JJ
as  ||| S:1134 E:1137 ||| IN
hypertension  ||| S:1137 E:1150 ||| NN
and  ||| S:1150 E:1154 ||| CC
sleep  ||| S:1154 E:1160 ||| VB
dis-  ||| S:1160 E:1165 ||| JJ
orders  ||| S:1165 E:1172 ||| NNS
could  ||| S:1172 E:1178 ||| MD
be  ||| S:1178 E:1181 ||| VB
of  ||| S:1181 E:1184 ||| IN
particular  ||| S:1184 E:1195 ||| JJ
importance ||| S:1195 E:1205 ||| NN
.  ||| S:1205 E:1207 ||| .
